Serina Therapeutics (SER) Short term Debt (2020 - 2025)

Serina Therapeutics has disclosed Short term Debt across 6 years of filings, most recently posting $2.9 million for Q3 2025.

• In Q3 2025, Short term Debt fell 72.4% year-over-year to $2.9 million; the TTM figure through Sep 2025 stood at $2.9 million (down 72.4% YoY), while the FY2022 annual figure was $7.6 million, up 7.09% from the prior year.
• Short term Debt came in at $2.9 million for Q3 2025 at Serina Therapeutics, down from $10.5 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $22.9 million in Q2 2023 to a low of $1.5 million in Q3 2023.
• Average Short term Debt over 5 years is $10.0 million, with a median of $8.7 million recorded in 2022.
• Year-over-year, Short term Debt surged 1537.61% in 2021 and sank 79.09% in 2023.
• Over 5 years, Short term Debt stood at $7.1 million in 2021, then grew by 7.09% to $7.6 million in 2022, then sank by 80.04% to $1.5 million in 2023, then jumped by 585.58% to $10.5 million in 2024, then plunged by 72.4% to $2.9 million in 2025.
• Per Business Quant data, the three most recent Short term Debt figures were $2.9 million in Q3 2025, $10.5 million in Q3 2024, and $10.4 million in Q2 2024.